Predictive role of homologous recombination deficiency (HRD) for irinotecan in combination with venadaparib, a novel PARP1/2 inhibitor, as third- or fourth-line treatment in patients with advanced gastric cancer.

Autor:	Oh, Do-Youn, Ryu, Min-Hee, Lee, Keun-Wook, Rha, Sun Young, Kim, Seung Tae, Iqbal, Syma, Yoon, Jeesun, Kim, Hyung-Don, Kim, Jin Won, Kim, Ji-Won, Lee, Won Sik, Hong, Min Ju, Lee, Myongjae, Roh, Eun-Jihn, HA, KYOUNG SOO
Zdroj:	Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p380-380, 185p
Databáze:	Supplemental Index
Externí odkaz:	Zobrazit plný text záznamu